Axogen (AXGN) vs CapsoVision (CV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Axogen (AXGN) has outperformed CapsoVision (CV) over the past year, gaining 113.3% versus a gain of 38.9%. Axogen is the larger company by market cap ($2.11 billion vs $348.0 million), about 6.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | CV |
|---|---|---|
| Share price | $36.04 | $6.54 |
| Market cap | $2.11B | $348.00M |
| 1-day change | -0.74% | +0.62% |
| YTD return | +10.11% | -38.82% |
| 1-year return | +113.25% | +38.85% |
| 5-year return | +164.61% | — |
| Forward P/E | 52.38 | — |
| EPS (TTM) | $-0.67 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.91 | $15.37 |
| 52-week low | $15.27 | $4.38 |
| Distance from 52-week high | -31.88% | -57.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +49.33% | +45.26% |
| Average volume | 1.22M | 158.95K |
| Shares outstanding | 58.67M | 53.21M |
| Employees | 622 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Axogen is about 6.1 times larger than CapsoVision by market value ($2.11B vs $348.00M).
- AXGN has outperformed CV by 74.4 percentage points over the past year.
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
AXGN vs CV FAQ
Which is bigger, Axogen or CapsoVision?
Axogen (AXGN) is larger, with a market capitalization of $2.11B compared with $348.00M for CapsoVision (CV).
Which stock has performed better over the past year, AXGN or CV?
AXGN returned +113.25% over the past 12 months, compared with +38.85% for CV (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and CapsoVision in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.